Article

Deferoxamine as adjunct therapeutics for tuberculosis

2023-06-02

Abstract excerpt

Dysregulated iron metabolism is reported in tuberculosis patients; therefore, it represents an opportunity for developing host-directed therapeutics. This study monitored the antimycobacterial properties of an iron chelator, i.e., Deferoxamine (DFO/D), and its impact on the transcript and metabolite levels of Mycobacterium tuberculosis (Mtb) in vitro . For in vivo validation, a group of mice received ferric car...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3de07a81-fa3b-5365-b14f-f21f6aee9a21
DOI: 10.1101/2023.06.02.543389

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Deferoxamine as adjunct therapeutics for tuberculosisDOI 10.1101/2023.06.02.543389Read

Iron limitation in M. tuberculosis has broad impact on central carbon metabolismSemantic proximity Read

An oxadiazole-based compound potentiates anti-tuberculosis treatment by increasing host resistance via zinc poisoningSemantic proximity Read

The Iron Response of Mycobacterium tuberculosis and Its Implications for Tuberculosis Pathogenesis and Novel TherapeuticsSemantic proximity Read

The past, present and future of tuberculosis treatment.Semantic proximity Read

Genome mining of Mycobacterium tuberculosis: targeting SufD as a novel drug candidate through in silico characterization and inhibitor screeningSemantic proximity Read

The role of thioredoxin proteins in <i>Mycobacterium tuberculosis</i> probed by proteome-wide target profilingSemantic proximity Read

NSAIDS-XDR-TB clinical trial: A randomized pilot study to estimate the potential efficacy and safety of using adjunctive ibuprofen for the treatment of pre-XDR and XDR tuberculosisSemantic proximity Read

Targeting the Proteostasis Network for Mycobacterial Drug DiscoverySemantic proximity Read

Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage.Semantic proximity Read

Molecular, biochemical and pharmacological characterisation of Mycobacterium tuberculosis cytochrome bd-I oxidase : a putative therapeutic targetSemantic proximity Read

Moxifloxacin-mediated killing of <i>Mycobacterium tuberculosis</i> involves respiratory downshift, reductive stress, and ROS accumulationSemantic proximity Read

Identification of a new mycobacterial peptide that controls the activity of the iron-dependent regulator, IdeRSemantic proximity Read